ライフサイエンスコーパス: bacteremia

1 ment duration for infections associated with bacteremia.

2 ntly causes severe invasive disease, such as bacteremia.

3 e of bacteremia, especially during S. aureus bacteremia.

4 mplicated PNA, UTI, or ABSSSI and associated bacteremia.

5 ation of NESp and increased virulence during bacteremia.

6 ents specifically with Staphylococcus aureus bacteremia.

7 ad short, 28% intermediate, and 9% prolonged bacteremia.

8 s for the prevention of postdental procedure bacteremia.

9 provide for an effective cure the persistent bacteremia.

10 ISPR)-Cas9, sensitized P9 pups to E. coli K1 bacteremia.

11 aureus bacteremia, 48.5% (SE, 0.4%) had MRSA bacteremia.

12 e prompt initiation of effective therapy for bacteremia.

13 phy in consecutive patients with E. faecalis bacteremia.

14 me was the incidence of postdental procedure bacteremia.

15 ospitals between 2000-2011 with pneumococcal bacteremia.

16 PC-Kp infections, especially those involving bacteremia.

17 and in a subgroup excluding catheter-related bacteremia.

18 cells in culture and lethality during mouse bacteremia.

19 illin-resistant Staphylococcus aureus (MRSA) bacteremia.

20 in methicillin-susceptible S. aureus (MSSA) bacteremia.

21 ity and mortality in patients with S. aureus bacteremia.

22 mes develop into systemic infections such as bacteremia.

23 have shown improved length of stay (LOS) in bacteremia.

24 considered in all patients with E. faecalis bacteremia.

25 sed alveolar tissue destruction and systemic bacteremia.

26 The negative-control outcome was gut-origin bacteremia.

27 curred in 3.2% of cases, with no FMT-related bacteremia.

28 revalence of IE in patients with E. faecalis bacteremia.

29 uided antibiotic management in patients with bacteremia.

30 ter treatment for subjects with pneumococcal bacteremia.

31 ere correlated with mortality and persistent bacteremia.

32 outcomes in daptomycin-treated enterococcal bacteremia.

33 or clinicians in the management of S. aureus bacteremia.

34 nt in the treatment of Staphylococcus aureus bacteremia.

35 revalence of IE in patients with E. faecalis bacteremia.

36 lungs and airways, with repeated episodes of bacteremia.

37 reduce mortality rates in patients with MSSA bacteremia.

38 g rates of colonized patients progressing to bacteremia.

39 use in humans of urinary tract infection and bacteremia.

40 tam as definitive treatment of P. aeruginosa bacteremia.

41 tion of treatment to impact outcomes in MSSA bacteremia.

42 respiratory and urinary tract infections and bacteremia.

43 e to recurrent nontyphoidal Salmonella (NTS) bacteremia.

44 motes acute inflammation, tissue damage, and bacteremia.

45 g clinical isolates of S. marcescens causing bacteremia.

46 2018 among 352 hospitalized adults with MRSA bacteremia.

47 concerning clinical pathogen, causing fatal bacteremia.

48 based on the daily probability of acquiring bacteremia.

49 The negative control outcome was gut-origin bacteremia.

50 italized patients with Staphylococcus aureus bacteremia.

51 w, moderate, and high pretest probability of bacteremia.

52 . aureus and methicillin-sensitive S. aureus bacteremia.

53 Of the 514 patients with MSSA bacteremia, 164 were excluded as they had received combi

54 mong adults with uncomplicated gram-negative bacteremia, 30-day rates of clinical failure for CRP-gui

55 rd error [SE], 1905) patients with S. aureus bacteremia, 48.5% (SE, 0.4%) had MRSA bacteremia.

56 ients with coagulase negative Staphylococcus bacteremia (5.5d and 4.5d vs 7.2d; P=0.003) in AXDX, AXD

57 ,514 blood culture days, with 3,762 cases of bacteremia (7.5%) and 370 cases of fungemia (0.7%).

58 ly alarming that probiotic strains can cause bacteremia(8,9), yet direct evidence for an ancestral li

59 Of the patients with NTS bacteremia, 969 (69%) had a cardiovascular condition and

60 For enterococcal bacteremia, a daptomycin fAUC/MIC >27.43 was associated

61 osa from the bloodstream to the feces during bacteremia, a process that promotes transmission in this

62 , or treatment failure in patients with MRSA bacteremia: a randomized clinical trial.

63 nd compared with patients with uncomplicated bacteremia (absence of any of the risk factors and no kn

64 In patients hospitalized with gram-negative bacteremia achieving clinical stability before day 7, an

65 Among patients with MRSA bacteremia, addition of an antistaphylococcal beta-lacta

66 Patients with septic shock and S. aureus bacteremia admitted directly from the emergency departme

67 his patient developed acute pancreatitis and bacteremia after the procedure.

68 the least incidence of postdental procedure bacteremia among all oral or topical forms of prophylact

69 rventions in preventing postdental procedure bacteremia among all the oral/topical forms of intervent

70 the least incidence of postdental procedure bacteremia among all the prophylactic interventions (odd

71 rt that probiotic strains can directly cause bacteremia and adaptively evolve within ICU patients.

72 and who had a history of serious infection (bacteremia and associated sternal osteomyelitis, infecti

73 of blood proteins at initial presentation of bacteremia and disease severity outcomes using 2 cohorts

74 al study in the treatment of refractory MSSA bacteremia and endocarditis.

75 nvasive organ dissemination during S. aureus bacteremia and for studying bacterial dynamics during mi

76 ical strategies for persistent and relapsing bacteremia and found that a persister killer, but not a

77 Bacteremia and fungemia can cause life-threatening illne

78 identified patients at low and high-risk for bacteremia and fungemia using routinely collected electr

79 Patients with MRSA bacteremia and g.25498283A > C genotype exhibited signif

80 cantly suppressed in patients with S. aureus bacteremia and in S. aureus-challenged primary human mac

81 Loss of spxB, pdhC or pfl2 decreased bacteremia and increased host survival.

82 and Mcpt-4, were observed concurrently with bacteremia and increased intestinal permeability.

83 The early diagnosis of bacteremia and initiation of treatment saves lives, espe

84 reatening invasive diseases such as empyema, bacteremia and meningitis.

85 diagnosis can be elusive due to intermittent bacteremia and normal echocardiography.

86 Bacteremia and other invasive bacterial infections are c

87 we have shown that DprA is important in both bacteremia and pneumonia infections.

88 streptococcus, or GBS) is a common cause of bacteremia and sepsis in newborns, pregnant women, and i

89 infection, cellulitis and osteomyelitis, and bacteremia and sepsis).

90 infection, cellulitis and osteomyelitis, and bacteremia and sepsis).

91 drug-resistant infections that often lead to bacteremia and sepsis.

92 A total of 506 patients with S. aureus bacteremia and septic shock were included in the analysi

93 nses to BPI can arise acutely in response to bacteremia and that this association is not limited to P

94 otection of the neonatal rat from E. coli K1 bacteremia and tissue invasion.

95 etermine prevalence and common etiologies of bacteremia and to inform a diagnostic approach to reliev

96 was significantly associated with prolonged bacteremia and worse outcomes.

97 Most common infections were bacteremia and/or endocarditis (73.5%), bone and/or join

98 onizing bacteria across the small intestine, bacteremia, and invasion of the meninges, with animals f

99 ng bacterial burdens, increased incidence of bacteremia, and lower survival rates.

100 atory distress, vascular leakage, high-level bacteremia, and often death within days.

101 ure infections (SSSI), Staphylococcus aureus bacteremia, and right-sided endocarditis infections asso

102 location, serum interleukin-6 (IL-6) levels, bacteremia, and sepsis mortality.

103 ses diverse infections, including pneumonia, bacteremia, and wound infections.

104 ab, the rate of a CPE carrier progressing to bacteremia; and deltac, the progression rate to nonbacte

105 above 65 years were more likely to have NTS bacteremia (AOR, 1.54 [95% CI, 1.46 to 1.67]; 2.57 [95%

106 Mortality rates from Staphylococcus aureus bacteremia are high and have only modestly improved in r

107 tment strategies to improve survival in MSSA bacteremia are urgently needed.

108 Patients with bacteremia, arthroscopic debridements and a follow-up <1

109 Patients with bacteremia, arthroscopic debridements, and a follow-up <

110 ed Kaplan-Meier curve applied after treating bacteremia as censoring events.

111 anging epidemiology of Staphylococcus aureus bacteremia, as well as the variables associated with poo

112 with Staphylococcus aureus and enterococcus bacteremia associated with worse outcomes.

113 isolates recovered from separate episodes of bacteremia at a single academic institution in Toronto,

114 e, 4.5%; 95% CI, -3.7% to 12.7%); persistent bacteremia at day 5 was observed in 19 of 166 (11%) vs 3

115 a 90-day composite of mortality, persistent bacteremia at day 5, microbiological relapse, and microb

116 mortality at days 14, 42, and 90; persistent bacteremia at days 2 and 5; acute kidney injury (AKI); m

117 e rapid, sensitive and accurate diagnosis of bacteremia at the point of need.

118 models resulting in resolving or persistent bacteremia, based on the total SA exceeding a detection

119 er >=38 degrees C for >=12 h and/or S. Typhi bacteremia) between participants challenged with wild-ty

120 sms are a major cause of gastroenteritis and bacteremia, but little is known about maternally acquire

121 A subset of bacteremia cases are caused by organisms not detected by

122 he average LOS that would be observed if all bacteremia cases could be prevented was multiplied by th

123 Anaerobes were identified in 57% of the bacteremia cases from the NB-PC group by conventional me

124 total number of extra ICU days caused by 666 bacteremia cases was estimated at 2453 (95% confidence i

125 We separated states into bacteremia caused by Gram-positive cocci (GPC), suscepti

126 We separated states into bacteremia caused by gram-positive cocci, susceptible gr

127 Persistent bacteremia caused by Staphylococcus aureus (SA), especia

128 Nontyphoidal Salmonella (NTS) bacteremia causes hospitalization and high morbidity and

129 ured by the numbers of Staphylococcus aureus bacteremia, Clostridium difficile infection, and vancomy

130 ck (cohort 1) and 88 patients with S. aureus bacteremia (cohort 2).

131 Patients with risk factors for complicated bacteremia (community acquisition, persistently positive

132 uding adults hospitalized with gram-negative bacteremia conducted in 3 Swiss tertiary care hospitals

133 r endocarditis was protective and persistent bacteremia constituted the sole risk factor for relapse.

134 (no oral switch); patients with concomitant bacteremia could receive up to 14 days.

135 The primary data points were bacteremia (daily), body temperature and heart rate (con

136 ntext of longitudinal surgical registers and bacteremia data, we describe a valuable approach to adju

137 , in a patient who developed a break-through bacteremia despite taking antibiotics to which the S. ep

138 mphiphilic pathogen biomarkers indicative of bacteremia, directly in aqueous blood, by mimicking inna

139 esent, most streptococci or Enterobacterales bacteremias do not require routine follow-up blood cultu

140 st-PCV eras, the prevalence of S. pneumoniae bacteremia dropped across all age groups (from 32.4% to

141 De-escalation in patients with monomicrobial bacteremia due to Enterobacteriaceae was not associated

142 aureus bacteremia (SaB) are associated with bacteremia duration and mortality.

143 aureus bacteremia (SaB) are associated with bacteremia duration and mortality.

144 30-day mortality were progressively worse as bacteremia duration increased (P < .0001).

145 ine the risk of poor outcomes in relation to bacteremia duration.

146 Patients were grouped by bacteremia duration: short (1-2 days), intermediate (3-6

147 ibiotic therapy did not significantly affect bacteremia duration; however, time to source-control pro

148 ended in syndromes with a high likelihood of bacteremia (eg, endovascular infections) and those with

149 The bacteremia, endotoxemia, and systemic low-grade inflamma

150 sk of becoming infected during an episode of bacteremia, especially during S. aureus bacteremia.

151 In contrast, sera from patients with bacteremia exhibited low avidity.

152 port a markedly higher risk of Lactobacillus bacteremia for intensive care unit (ICU) patients treate

153 sma, and is very useful for the diagnosis of bacteremia from clinical samples.

154 ly been associated with several outbreaks of bacteremia from contaminated pharmaceutical products.

155 infection (pyelonephritis) or urinary-source bacteremia, from non-invasive UPEC, defined as isolates

156 us aureus bacteremia (SAB) and gram-negative bacteremia (GNB) to compare the characteristics, outcome

157 In the bacteremia group, MRI studies were normal and neuropatho

158 ), defined as 30-day mortality or persistent bacteremia >=7 days.

159 r than that of a matched cohort whose KPC-Kp bacteremia had been treated with drugs other than CAZ-AV

160 o difference between MRSA and MSSA, but MRSA bacteremia had more readmission for bacteremia recurrenc

161 The gradient boosting machine model for bacteremia had significantly higher area under the recei

162 ivariate analysis of the 208 cases of KPC-Kp bacteremia identified septic shock, neutropenia, Charlso

163 tissue infection was present in 50%, sepsis/bacteremia in 52%, osteomyelitis in 10%, and endocarditi

164 mast cell activation and malaria-associated bacteremia in a rodent model.

165 munogenic and effective in reducing S. Typhi bacteremia in children 9 months to 16 years of age.

166 erial burden in the nasopharynx and enhanced bacteremia in mice.

167 in-flora-related, or central-line-associated bacteremia in patients with hematological malignancies w

168 in flora-related, or central line-associated bacteremia in patients with hematological malignancies w

169 urgent need for a rapid method for detecting bacteremia in pediatric patients with co-morbidities to

170 The frequency and persistence of bacteremia in the absence of clinical symptoms was notab

171 up with over 30 times the occurrence rate of bacteremia in the low-risk group (27.4% vs 0.9%; p < 0.0

172 d in approximately 1 in 2000 inpatients with bacteremia in this large cohort of NIS inpatients.

173 ar with appropriate anti-MRSA therapy during bacteremia in vivo.

174 set to study the trends and outcomes of NTS bacteremias in England between 2004 and 2015.

175 lar bacterial cell numbers (ie, the level of bacteremia), in patients at the time of clinical present

176 tion of meningitis, bacteremic pneumonia, or bacteremia (including hearing loss, developmental delay,

177 lin-susceptible Staphylococcus aureus (MSSA) bacteremia, including immediate clearance (<=24 hours) i

178 Proportions of bacteremia increased from 1.41% in 2004 to 2.67% in 2015

179 e further assessed, if PCT can reflect early bacteremia induced by non-surgical periodontal treatment

180 level cytomegalovirus viremia, gram-negative bacteremia, invasive mold infection, acute and chronic g

181 Gram-negative bacteremia is a common infection that results in substan

182 Bacteremia is a leading cause of death in sub-Saharan Af

183 Gram-negative bacteremia is a major cause of morbidity and mortality i

184 illin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with mortality of more than 20%

185 MRSA bacteremia is associated with readmission for bacteremia

186 However, diagnosing bacteremia is challenging for clinicians, especially in

187 Thirty-day readmission after S. aureus bacteremia is common and costly.

188 Postdental procedure bacteremia is common and troublesome.

189 ity testing (AST) in Gram-negative rod (GNR) bacteremia is compelling; however, evidence supporting i

190 ntibiotic regimen for Pseudomonas aeruginosa bacteremia is controversial.

191 for patients at risk of adverse events if a bacteremia is missed (eg, patient with pacemaker and sev

192 illin-resistant Staphylococcus aureus (MRSA) bacteremia is not well understood.

193 hallenge, although only 7% of mice presented bacteremia, LF and EF were detected in the blood of 100%

194 h a non-inferiority margin of 10%: recurrent bacteremia, local suppurative complication, distant comp

195 NTS bacteremia mainly affects older people with comorbiditie

196 cerebral vasculitis, promoted by a systemic bacteremia-mediated inflammation.

197 During bacteremia, mice infected with the pbgA mutants survived

198 expression, and attenuated virulence in the bacteremia model as compared to their respective parenta

199 Here, we utilized a mouse bacteremia model to quantify the virulence of 100 indivi

200 ced MRSA eradication by oxacillin in a mouse bacteremia model.

201 grA on virulence was evaluated using a mouse bacteremia model.

202 tients had higher Pitt scores and persistent bacteremia more often than BL-M patients.

203 een after inoculation via the tail vein in a bacteremia mouse model.

204 oup (n = 11/23, 48%), when compared with the bacteremia (n = 1/11, 9%; p = 0.03) and nonbacterial thr

205 s using 2 cohorts of patients with S. aureus bacteremia (n = 32 and n = 124).

206 atients with invasive Salmonella Typhimurium bacteremia (n = 7) and those with Staphylococcal bactere

207 eremia (n = 7) and those with Staphylococcal bacteremia (n = 7) with 100% correlation with confirmato

208 compared with three other conditions, namely bacteremia, nonbacterial thrombotic endocarditis, and he

209 In bacteremia, observational data support prescription of h

210 -lactamase (ESBL)-producing Escherichia coli bacteremia occurred after they had undergone FMT in two

211 nt upon the growth kinetics or the levels of bacteremia of B. pseudomallei represent the next-generat

212 TGR in endothelial cells results in very low bacteremia, optimal sensitivity of qPCR for these ricket

213 condary to sepsis, occurring in 0.04-0.5% of bacteremia or fungemia.

214 Many patients have known or suspected bacteremia or fungemia; however, culture yield is report

215 We identified all patients diagnosed with bacteremia or sepsis, endocarditis, osteomyelitis or sep

216 impacts human gut microbiota as a prelude to bacteremia or whether antimalarials affect gut microbiot

217 CI: 1.26 to 4.40; p = 0.007), monomicrobial bacteremia (OR: 2.73; 95% CI: 1.23 to 6.05; p = 0.013),

218 ls were elevated in patients with persistent bacteremia (P < .0001), endovascular (P = .026) and meta

219 vated in mortality (P = .008) and persistent bacteremia (P = .034), while no difference occurred in I

220 on with an agr group III organism (P = .04), bacteremia (P = .04), delayed source control (P < .001),

221 tcomes of mortality (P=0.008) and persistent bacteremia (P=0.034), while no difference occurred in IL

222 ococcus aureus (MSSA and MRSA, respectively) bacteremia, particularly readmission, is scarce and requ

223 reactivity by examining antibodies to BPI in bacteremia patients.

224 the best performance to classify malaria and bacteremia patients.

225 ts with uncomplicated Pseudomonas aeruginosa bacteremia, patients receiving short-course (median, 9 d

226 h persistent methicillin-resistant S. aureus bacteremia (PB) and resolving methicillin-resistant S. a

227 ed infections such as Pseudomonas aeruginosa bacteremia pose a major clinical risk for hospitalized p

228 ibutes to increased capacity to resolve MRSA bacteremia, potentially through a mechanism involving in

229 icrobiota, which, when excluded, reduced the bacteremia rate to 1.6%.

230 nd resolving methicillin-resistant S. aureus bacteremia (RB) matched by sex, age, race, hemodialysis

231 This meta-analysis of patients with bacteremia receiving PCT-guided antibiotic management de

232 but MRSA bacteremia had more readmission for bacteremia recurrence (hazard ratio, 1.17 [95% confidenc

233 Readmission with bacteremia recurrence was particularly more common among

234 acteremia is associated with readmission for bacteremia recurrence, increased mortality, and longer h

235 verall, and $19 186 (SE, $623) in those with bacteremia recurrence.

236 antistaphylococcal beta-lactam on mortality, bacteremia, relapse, or treatment failure in patients wi

237 composite end point of mortality, persistent bacteremia, relapse, or treatment failure.

238 h the highest risk for treatment failure and bacteremia-related complications, providing a valuable t

239 ified with perinatal infections, candidemia, bacteremia, respiratory disorders, or ROP.

240 wth of the same organism causing the initial bacteremia), restarting gram-negative-directed antibioti

241 study of patients with Staphylococcus aureus bacteremia (SAB) and gram-negative bacteremia (GNB) to c

242 -10 responses early in Staphylococcus aureus bacteremia (SaB) are associated with bacteremia duration

243 early in the course of Staphylococcus aureus bacteremia (SaB) are associated with bacteremia duration

244 Staphylococcus aureus bacteremia (SaB) causes significant disease in humans, c

245 Persistent Staphylococcus aureus bacteremia (SAB) is defined based on varying duration in

246 Staphylococcus aureus bacteremia (SAB) is uniquely characterized by focal pyog

247 roduction and its association with S. aureus bacteremia (SaB) mortality.

248 disease management of Staphylococcus aureus bacteremia (SAB) was surveyed through the Emerging Infec

249 atients with high-risk Staphylococcus aureus bacteremia (SAB), because of the risk for metastatic inf

250 ured by the numbers of Staphylococcus aureus bacteremia (SAB), Clostridium difficile infection (CDI)

251 omatic colonization to a marker of S. aureus bacteremia (SAB).

252 teral therapy (SPT) in Staphylococcus aureus bacteremia (SAB).

253 ortant complication of Staphylococcus aureus bacteremia (SAB).

254 feared complication of Staphylococcus aureus bacteremia (SAB).

255 The Pitt bacteremia score (PBS) is commonly used as a predictor o

256 use of serious nosocomial infections such as bacteremia, sepsis, and endocarditis.

257 rongly suspected (ie, gas in the collection, bacteremia, sepsis, or clinical deterioration).

258 itis (422 cases), pneumonia (399 cases), and bacteremia/septicemia (280 cases).

259 ion, pneumonia, cellulitis/osteomyelitis, or bacteremia/septicemia.

260 26% definite IE in patients with E. faecalis bacteremia, suggesting that echocardiography should be c

261 Based on the reported incidence of bacteremia, syndromes were categorized into low, moderat

262 filtration at the infectious foci, increased bacteremia, systemic inflammatory response, and multiorg

263 of infection that may contribute to enteric bacteremia that is associated with malaria.

264 ic treatment for uncomplicated gram-negative bacteremia to 7 days is an important antibiotic stewards

265 767 hospitalized patients with P. aeruginosa bacteremia treated with beta-lactam monotherapy during 2

266 l study of 265 hospitalized adults with MRSA bacteremia treated with vancomycin.

267 udy focusing on intensive care unit-acquired bacteremia using data from 2 general intensive care unit

268 We identified MSSA and MRSA bacteremia using International Classification of Disease

269 ssion were perinatal infections, candidemia, bacteremia, very low birth weight, prematurity, respirat

270 Every continued day of bacteremia was associated with a relative risk of death

271 ICU-acquired bacteremia was associated with a substantial excess LOS.

272 But, fourth, when relapsing bacteremia was considered, the growth rate of persister

273 Salmonella bacteremia was found in only 16 to 29% and 0% of mice wi

274 Sensitivity was not compromised: true bacteremia was noted in 65/904 (7.2%) ISDD vs 69/904 (7.

275 A retrospective cohort study of MSSA bacteremia was performed in a tertiary hospital from Jan

276 The duration of bacteremia was significantly longer in participants chal

277 The rate of bacteremia was significantly lower among COVID-19 patien

278 s that discriminate resolving and persistent bacteremia, we applied a machine learning approach and f

279 Using a murine model of recurrent bacteremia, we demonstrate that infection with a leukoci

280 clinical outcomes in patients with S. aureus bacteremia, we evaluated the association between a panel

281 s for the prevention of postdental procedure bacteremia were eligible.

282 reus (MRSA), streptococcal, and pneumococcal bacteremia were found to significantly increase the risk

283 A total of 344 patients with E. faecalis bacteremia were included, all examined using echocardiog

284 The sources of bacteremia were more frequently unknown for the NB-PC gr

285 otic treatment for PNA, UTI, and ABSSSI with bacteremia were not associated with increased overall ri

286 Malaria strongly predisposes to bacteremia, which is associated with sequestration of pa

287 Inpatients with gram-negative bacteremia, who were afebrile and hemodynamically stable

288 g the low-risk cut-off, the model identifies bacteremia with 98.7% sensitivity.

289 the lux signal in a mouse model of S. aureus bacteremia with a sensitivity of approximately 3 x 10(4)

290 er brucellosis until they were notified that bacteremia with Brucella was suspected.

291 ptococcus pneumoniae infection can result in bacteremia with devastating consequences including heart

292 od from positive blood culture broth for GNR bacteremia with electronic isolate-specific de-escalatio

293 ls of sepsis (cecal ligation and puncture or bacteremia with Escherichia coli or Streptococcus pneumo

294 n cohorts, demonstrating associations of Mtb bacteremia with progressive phenotypes of latent infecti

295 classified as a 'missed' PJI at the time of bacteremia with S. aureus (1.1%).

296 rdiac surgery, embolic events, or relapse of bacteremia with the primary pathogen, from the time of r

297 PD patients experience low-grade bacteremias with oral microbes implicated in the risk of

298 es of methicillin-resistant S. aureus (MRSA) bacteremia, with a rising proportion due to MSSA (55% gr

299 terleukin-10 (IL-10) than patients with MRSA bacteremia without DNMT3A mutation (A/C: 9.7038 pg/mL vs

300 Staphylococcus aureus is a leading cause of bacteremia, yet there remains a significant knowledge ga